Alexander Snyder (2021) “For Profit or For Health? It is Time to Reckon With the Current Pharmaceutical Landscape Through a Systematic Analysis of Monoclonal Anitbodies”, Pittsburgh Journal of Technology Law & Policy, 21(2). doi: 10.5195/tlp.2021.251.